Literature DB >> 31580502

Prevalence and Correlates of Past-Year Recovery From DSM-5 Alcohol Use Disorder: Results From National Epidemiologic Survey on Alcohol and Related Conditions-III.

Amy Z Fan1, Sanchen Patricia Chou1, Haitao Zhang1, Jeesun Jung1, Bridget F Grant2.   

Abstract

BACKGROUND: Little is known about remission, recovery, and other outcomes of alcohol use disorder (AUD) as defined by the DSM-5.
METHODS: Data from a large representative sample of the United States was used to examine correlates of past-year AUD status among individuals with prior-to-past-year AUD: persistent AUD, symptomatic high-risk drinking, asymptomatic high-risk drinking, symptomatic low-risk drinking, asymptomatic low-risk drinking (nonabstinent recovery, NAR), and abstainer (abstinent recovery, AR). Multiple logistic regression analyses were conducted to compare: (i) AR and NAR with persistent AUD, (ii) AR with NAR, and (iii) asymptomatic and symptomatic high-risk drinking with AR and NAR.
RESULTS: Among individuals with AUD prior to past year (n = 7,785), 34.2% were classified with persistent AUD, 8.8 and 1.6% were symptomatic high-risk and symptomatic low-risk drinkers, respectively, 21.5% were asymptomatic high-risk drinkers, 17.9% were asymptomatic low-risk drinkers, and 16.0% were abstainers. One-quarter of individuals with AUD prior to past year achieved AR or NAR without the benefit of treatment, while a much greater percentage of individuals achieving AR (43.2%) reported receiving treatment relative to those with NAR (12.3%). The number of lifetime AUD symptoms was greater among those achieving AR (among the treated) and lower among those achieving NAR relative to persistent AUD. The number of AUD symptoms was also greater among those achieving AR than NAR and lower among asymptomatic and symptomatic risk drinkers relative to those achieving AR and NAR. Consumption was greater among those achieving AR relative to those achieving NAR and greater among asymptomatic and symptomatic risk drinkers relative to AR and NAR. Odds of achieving AR or NAR relative to persistent AUD were generally lower among non-Hispanic Blacks and those with higher education, greater among women and married individuals, and lower among illicit drug users and individuals with histories of a personality disorder or mood/anxiety disorder.
CONCLUSIONS: There appears to be a substantial level of recovery from AUD. Information on specific factors associated with AUD outcomes can be useful in targeting appropriate treatment efforts.
© 2019 by the Research Society on Alcoholism. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Entities:  

Keywords:  Alcohol Use Disorder; Correlates; DSM-5 Diagnosis; Epidemiology; Persistent Alcohol Use Disorder; Population Survey; Recovery; Remission

Year:  2019        PMID: 31580502     DOI: 10.1111/acer.14192

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  15 in total

1.  Preresolution Drinking Problem Severity Profiles Associated with Stable Moderation Outcomes of Natural Recovery Attempts.

Authors:  Jalie A Tucker; JeeWon Cheong; Tyler G James; Soyeon Jung; Susan D Chandler
Journal:  Alcohol Clin Exp Res       Date:  2020-02-18       Impact factor: 3.455

2.  Abstinence Not Required: Expanding the Definition of Recovery from Alcohol Use Disorder.

Authors:  Katie Witkiewitz; Jalie A Tucker
Journal:  Alcohol Clin Exp Res       Date:  2019-12-04       Impact factor: 3.455

3.  Momentary associations between stress and alcohol craving in the naturalistic environment: differential associations for Black and White young adults.

Authors:  Sarah L Pedersen; Traci M Kennedy; Jordan Holmes; Brooke S G Molina
Journal:  Addiction       Date:  2021-12-03       Impact factor: 6.526

4.  Abstinence versus moderation recovery pathways following resolution of a substance use problem: Prevalence, predictors, and relationship to psychosocial well-being in a U.S. national sample.

Authors:  David Eddie; Brandon G Bergman; Lauren A Hoffman; John F Kelly
Journal:  Alcohol Clin Exp Res       Date:  2022-01-04       Impact factor: 3.455

Review 5.  Understanding low treatment seeking rates for alcohol use disorder: A narrative review of the literature and opportunities for improvement.

Authors:  Alexandra Venegas; Suzanna Donato; Lindsay R Meredith; Lara A Ray
Journal:  Am J Drug Alcohol Abuse       Date:  2021-08-31       Impact factor: 3.912

6.  Remission From Unhealthy Drinking Among Patients With an Alcohol Use Disorder: A Longitudinal Study Using Systematic, Primary Care-Based Alcohol Screening Data.

Authors:  Vanessa A Palzes; Andrea H Kline-Simon; Derek D Satre; Stacy Sterling; Constance Weisner; Felicia W Chi
Journal:  J Stud Alcohol Drugs       Date:  2020-07       Impact factor: 2.582

7.  Epigallocatechin-3-gallate improves chronic alcohol-induced cognitive dysfunction in rats by interfering with neuro-inflammatory, cell death and oxido-nitrosative cascade.

Authors:  Ankit Uniyal; Vineeta Tiwari; Anagha Gadepalli; Obulapathi Ummadisetty; Vinod Tiwari
Journal:  Metab Brain Dis       Date:  2021-08-12       Impact factor: 3.584

8.  Shifts in behavioral allocation patterns as a natural recovery mechanism: Postresolution expenditure patterns.

Authors:  Jalie A Tucker; JeeWon Cheong; Susan D Chandler
Journal:  Alcohol Clin Exp Res       Date:  2021-05-11       Impact factor: 3.928

9.  Predictors of early and sustained cessation of heavy drinking over 5 years among adult primary care patients.

Authors:  Vanessa A Palzes; Andrea H Kline-Simon; Derek D Satre; Stacy Sterling; Constance Weisner; Felicia W Chi
Journal:  Addiction       Date:  2021-07-12       Impact factor: 6.526

10.  Individual Differences in Ethanol Drinking and Seeking Behaviors in Rats Exposed to Chronic Intermittent Ethanol Vapor Exposure is Associated with Altered CaMKII Autophosphorylation in the Nucleus Accumbens Shell.

Authors:  Sucharita S Somkuwar; Chitra D Mandyam
Journal:  Brain Sci       Date:  2019-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.